An interventional study of Ultrasound-guided percutaneous cryoablation of thyroid neoplasm and Ultrasound-guided percutaneous microwave ablation of thyroid neoplasm in Thyroid Tumor and Thyroid Neoplasm, sponsored by Yukun Luo. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Yukun Luo · Not applicable, Interventional, and Treatment
The goal of this clinical study is to learn if cryoablation works to treat thyroid tumors. It will also learn about the safety of cryoablation for thyroid tumors. The main questions it aims to answer are:
Participants will receive cryoablation treatment guided by ultrasound. Researchers will track tumor size changes and check for any safety issues during follow-up visits.
785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.
This study's planned enrollment of 108 is above the median of 53 across 520 interventional studies indexed under Thyroid Neoplasms.
Browse Thyroid Neoplasms studies →This is the only study on the registry with Yukun Luo as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
【Group 1: Papillary Thyroid Carcinoma (PTC) patients】
【Group 2: Benign thyroid nodule patients】
Exclusion Criteria:
【Group 1: Papillary Thyroid Carcinoma (PTC) patients】
(1) confirms high-risk subtype papillary thyroid carcinoma; (2) History of thyroid surgery or radiotherapy; (3) Complicated with malignant tumors in other sites; (4) Severe coagulation dysfunction, or patients taking oral anticoagulants who have not reached the required drug-withdrawal period; (5) Incomplete follow-up data. 【Group 2: Benign thyroid nodule patients】
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive conventional ultrasound-guided microwave ablation.
Procedure: Ultrasound-guided percutaneous microwave ablation of thyroid neoplasm
Participants undergo ultrasound-guided cryoablation, the investigational treatment evaluated in this study.
Procedure: Ultrasound-guided percutaneous cryoablation of thyroid neoplasm
Under local anesthesia, ultrasound-guided percutaneous cryoablation is applied to treat thyroid neoplasms. Targeted tumor tissue is destroyed by ultralow temperature from cryoprobes.
Ultrasound-guided percutaneous microwave ablation of thyroid neoplasm
Tumor Volume Reduction Rate (VRR) at 12 months after ablation
Tumor volume is measured by two-dimensional thyroid ultrasound before treatment and at 12-month follow-up. Volume Reduction Rate (%) = (Baseline tumor volume - 12-month ablation zone volume) / Baseline tumor volume × 100%. Compare VRR between microwave ablation group and cryoablation group.
Time frame: Baseline (pre-ablation), 12 months after ablation
Complete tumor disappearance rate at 12 months
Complete disappearance is defined as no visible residual lesion and blurred ablation boundary on thyroid ultrasound \& contrast-enhanced ultrasound at 12-month follow-up. Count participants with complete lesion absorption in two groups.
Time frame: Baseline, 1, 3, 6, 12 months post-ablation
Incidence of treatment-related complications
Complications include transient hoarseness, hemorrhage, infection, nerve injury, thyroid dysfunction, etc. Divided into minor and major complications according to interventional radiology standard; record all adverse events from procedure to 12-month follow-up.
Time frame: Intraoperative, immediate post-op, 1 day, 1, 3, 6, 12 months after ablation
Postoperative pain visual analog scale (VAS) score
Pain scored by VAS (0-10 scale, 0=no pain, 10=worst pain imaginable), assessed at immediate post-procedure and postoperative day 1.
Time frame: Immediately after ablation, postoperative day 1
Total operation time
Total procedure duration from puncture to completion of ablation under ultrasound guidance for each participant.
Time frame: Intraoperative period only
Plan to share: No — Data cannot be shared publicly due to patient privacy protection, institutional data management regulations, and incomplete long-term follow-up data sorting.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.